Drug Database
Back to search

Finland· FI-REL-REL63800

Tresiba FlexPen

A insulin degludec product containing insulin degludec, registered in Finland by Novo Nordisk A/S. The same ATC class is registered in 14 of our 19 countries.

ATC A10AE06

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedTresiba FlexPenATCA10AE06REGISTER NO.FI-REL-REL63800PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about insulin degludecAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Insulin degludec is registered in 14 of 19 countries.

Countries holding a registration under ATC A10AE06 (insulin degludec), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose
Search insulin degludec products by name

Insulin degludec · ATC A10AE06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Insulin degludec
Manufacturer
Novo Nordisk A/S
Country
Finland (FI)
ATC code
A10AE06
ATC class
Insulin degludec
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

431 interactions on record for insulin degludec.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check insulin degludec against other medicinesHow interaction checks work

Insulin degludec · interactions on record

431 records

  • 15 severe
  • 366 moderate
  • 50 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • PrednisoloneA07EA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Insulin degludec in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin degludec products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Tresiba Flexpen, Tresiba Flextouch
  • Norway · Tresiba, Tresiba Flexpen

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/db48808f-d4d2-4705-be79-5ff908c48689
GET /v1/drugs/db48808f-d4d2-4705-be79-5ff908c48689?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "40",
  "form": "injektioneste, liuos, esitäytetty kynä",
  "route": "Ihon alle",
  "ddd_unit": "U",
  "strength": "100 U/ml",
  "atc_label": "degludekinsuliini",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/12/807/017",
  "fimea_rel_id": "REL63800",
  "authorised_at": "2025-02-10"
}
API referenceMCP serverPlans

See everything about insulin degludec.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console